Visby Medical
Founded Year
2012Stage
Grant - V | AliveTotal Raised
$470.23MValuation
$0000Last Raised
$3.9M | 3 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-85 points in the past 30 days
About Visby Medical
Visby Medical develops polymerase chain reaction (PCR)-based diagnostic tests for the detection of infectious diseases. The company offers medical solutions for sexual health tests, respiratory health tests, and other infectious diseases. It was formerly known as Click Diagnostics. The company was founded in 2012 and is based in San Jose, California.
Loading...
Loading...
Expert Collections containing Visby Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Visby Medical is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
Visby Medical Patents
Visby Medical has filed 39 patents.
The 3 most popular patent topics include:
- molecular biology
- medical tests
- biotechnology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/3/2019 | 3/4/2025 | Molecular biology, Cephalosporin antibiotics, Genetics, Antibiotics, Rare diseases | Grant |
Application Date | 9/3/2019 |
|---|---|
Grant Date | 3/4/2025 |
Title | |
Related Topics | Molecular biology, Cephalosporin antibiotics, Genetics, Antibiotics, Rare diseases |
Status | Grant |
Latest Visby Medical News
Feb 27, 2025
Visby Medical chief medical officer and Stanford University Medicine professor Dr Gary Schoolnik said: “This FDA decision ensures that accurate, rapid testing with the Visby Medical Respiratory Health Test will remain available to help physicians quickly diagnose and treat patients as they face upcoming respiratory seasons. “Fast diagnosis of patients with respiratory symptoms — enabling selection of the most appropriate treatments — is increasingly important to the medical community.” Offering results within 30 minutes, the test is tailored to improve patient care by enabling diagnoses at the point of care, particularly in remote and resource-limited settings. Visby’s platform provides “true” PCR technology, which is said to be the gold standard for testing influenzas A and B, and Covid-19. In December 2022, this multiplexed molecular test received emergency use authorisation from the FDA. The company’s project received support in whole or in part with funding from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), and the Administration for Strategic Preparedness and Response. Ongoing BARDA-funded studies aim to expand the device’s capabilities, potentially paving the way for an at-home respiratory test. Since its founding in 2012, Visby Medical has focused on streamlining the diagnosis and treatment process for infectious conditions. In 2021, the company received a $12.3m award from BARDA to expedite the development of its rapid, single-use Flu-Covid PCR Test. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Visby Medical Frequently Asked Questions (FAQ)
When was Visby Medical founded?
Visby Medical was founded in 2012.
Where is Visby Medical's headquarters?
Visby Medical's headquarters is located at 3010 North First Street, San Jose.
What is Visby Medical's latest funding round?
Visby Medical's latest funding round is Grant - V.
How much did Visby Medical raise?
Visby Medical raised a total of $470.23M.
Who are the investors of Visby Medical?
Investors of Visby Medical include CARB-X, Artiman Ventures, Pitango Venture Capital, John Doerr, +ND Capital and 22 more.
Who are Visby Medical's competitors?
Competitors of Visby Medical include Sense Biodetection and 1 more.
Loading...
Compare Visby Medical to Competitors
Nostics works as a healthcare technology company that specializes in point-of-care diagnostics within the medical diagnostics industry. The company provides pathogen identification solutions that assist healthcare providers in prescribing antibiotics during the initial patient consultation. Nostics' technology utilizes nanotechnology, photonics, and machine learning, producing results. Nostics was formerly known as Spektrax. It was founded in 2020 and is based in Amsterdam, Netherlands.
Biomerieux specializes in in vitro diagnostics within the healthcare sector, focusing on the development and manufacturing of diagnostic tests. The company offers a broad range of products that enable rapid and accurate detection of infectious diseases, antimicrobial resistance, and food safety concerns, as well as solutions for pharmaceutical quality control. These products serve various sectors including healthcare, food industry, and pharmaceuticals. It was founded in 1963 and is based in Marcy L'Etoile, France.
Oxford Nanopore Technologies (LSE: ONT.L) specializes in deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing technology within the biotechnology sector. The company offers products and solutions for DNA and RNA sequencing, including library preparation, sequencing devices, flow cells, and data analysis tools. Its products enable the analysis of genetic material for research in areas such as microbiology, human genetics, cancer, and environmental studies. It was founded in 2005 and is based in Oxford, United Kingdom.
Cue Health serves as a healthcare technology company specializing in diagnostic testing within the health sector. The company offers a portable molecular testing platform that provides lab-quality, actionable health insights quickly and conveniently. Cue Health primarily serves the healthcare industry, including clinics and individuals seeking at-home diagnostic solutions. It was founded in 2010 and is based in San Diego, California. In May 2024, Cue Health filed for bankruptcy.
Lucira Health specializes in at-home molecular testing for the healthcare sector. The company offers a test that identifies whether viral respiratory symptoms are due to COVID-19 or the flu, with results available in approximately 30 minutes. This test is for use at home and is available over-the-counter. Lucira Health was formerly known as Diassess. It was founded in 2013 and is based in Emeryville, California. In February 2023, Lucira Health filed for bankruptcy.
Sense Biodetection operates as a molecular diagnostics company. It designs and develops proprietary molecular and device technologies. The company serves hospitals, urgent care, nursing homes, workplace and campus health, community health, and travel sectors. The company was founded in 2014 and is based in Abingdon, U.K. In February 2023, Sense Biodetection was acquired by Sherlock Biosciences. The terms of the transaction were not disclosed.
Loading...